Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.37 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.37 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10964206 | 0.79 | GPR3 (0.56) | GPR3CYP1A2CYP2C19HTTLMNA | |
| SCHEMBL928001 | 0.77 | GPR3 (0.54) | GPR3CYP1A2CYP2C19HTTLMNA | |
| Benzonaphthyridine SCHEMBL51197 | 0.76 | GPR3 (1.00) | GPR3CYP1A2CYP2C19HTTLMNA | |
| Benzonaphthyridine SCHEMBL29600756 | 0.76 | GPR3 (1.00) | GPR3CYP1A2CYP2C19HTTLMNA | |
| Benzonaphthyridine SCHEMBL30897319 | 0.76 | GPR3 (1.00) | GPR3CYP1A2CYP2C19HTTLMNA | |
| SCHEMBL3260315 | 0.73 | GPR3 (0.45) | GPR3CYP1A2CYP2C19HTTNPC1 | |
| SCHEMBL30578353 | 0.73 | GPR3 (0.45) | GPR3CYP1A2CYP2C19HTTNPC1 | |
| SCHEMBL2512737 | 0.72 | KDM4E (0.56) | GPR3CYP1A2CYP2C19HTTLMNA | |
| SCHEMBL5840950 | 0.71 | KDM4E (0.44) | GPR3CYP1A2CYP2C19HTTLMNA | |
| SCHEMBL4727228 | 0.71 | GPR3 (0.52) | GPR3CYP1A2CYP2C19HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
| US-7651746-B2 | Halogenated bisdiarylaminopolycyclic aromatic compounds and polymers thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20070126345-A1 | Halogenated bisdiarylaminopolycylic aromatic compounds and polymers thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-07 | — | — | US | disclosed |
| WO-2005049546-A1 | HALOGENATED BISDIARYLAMINOPOLYCYLIC AROMATIC COMPOUNDS AND POLYMERS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | GPR3 2285/4885CYP1A2 338/4885CYP2C19 567/4885 |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | GPR3 1924/4885CYP1A2 567/4885CYP2C19 941/4885 |
| US-20070126345-A1 | Halogenated bisdiarylaminopolycylic aromatic compounds and polymers thereof | AHR, AADAC, ARNT | GPR3 1136/4885CYP1A2 133/4885CYP2C19 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.